Orexigen Therapeutics (OREX) Posts Q1 GAAP EPS of $1.12
Get Alerts OREX Hot Sheet
Join SI Premium – FREE
Orexigen Therapeutics (NASDAQ: OREX) reported Q3 EPS of $1.12, which might not compare with the analyst estimate of ($2.24). Revenue for the quarter came in at $7 million versus the consensus estimate of $8.17 million.
For the three months ended September 30, 2016, Orexigen reported net income of $47.7 million, or $3.27 per basic share, as compared to a net loss of $11.1 million, or $0.86 per basic share, for the third quarter of 2015. Excluding the elimination of deferred revenue and other business combination accounting adjustments associated with the completed acquisition of U.S. rights to Contrave, Orexigen would have incurred a net loss of $30.2 million for the three months ended September 30, 2016. A reconciliation from reported GAAP net income to non-GAAP net loss is provided at the end of this press release.
For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- Deutsche Bank (DB) Tops Q1 EPS by 1c
- Independent Bank (IBCP) Tops Q1 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!